Intra-Cellular Therapies Total Long Term Liabilities 2013-2024 | ITCI

Intra-Cellular Therapies total long term liabilities for the quarter ending September 30, 2024 were $0.014B, a 2.77% decline year-over-year.

  • Intra-Cellular Therapies total long term liabilities for 2023 were $0.013B, a 13.88% decline from 2022.
  • Intra-Cellular Therapies total long term liabilities for 2022 were $0.015B, a 17.14% decline from 2021.
  • Intra-Cellular Therapies total long term liabilities for 2021 were $0.019B, a 20.87% decline from 2020.

Intra-Cellular Therapies Total Long Term Liabilities 2013-2024 | ITCI

  • Intra-Cellular Therapies total long term liabilities for 2023 were $0.013B, a 13.88% decline from 2022.
  • Intra-Cellular Therapies total long term liabilities for 2022 were $0.015B, a 17.14% decline from 2021.
  • Intra-Cellular Therapies total long term liabilities for 2021 were $0.019B, a 20.87% decline from 2020.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$150.5B
Bristol Myers Squibb (BMY)$118.1B
Vertex Pharmaceuticals (VRTX)$115.4B
Gilead Sciences (GILD)$109.4B
CSL (CSLLY)$85.4B
Regeneron Pharmaceuticals (REGN)$81.8B
GSK (GSK)$69.3B
Argenex SE (ARGX)$34.4B
Alnylam Pharmaceuticals (ALNY)$30.2B
BioNTech SE (BNTX)$25.5B
Biogen (BIIB)$22.6B
Illumina (ILMN)$21.4B
BeiGene (BGNE)$18.3B
Moderna (MRNA)$14.3B
Incyte (INCY)$13.6B
Genmab (GMAB)$13.6B
Insmed (INSM)$13.2B
BioMarin Pharmaceutical (BMRN)$11.8B
Vaxcyte (PCVX)$10.9B
Bio-Techne Corp (TECH)$10.5B
Sarepta Therapeutics (SRPT)$10.2B
Exact Sciences (EXAS)$10B
Exelixis (EXEL)$9.8B
Revolution Medicines (RVMD)$9.5B
Bio-Rad Laboratories (BIO.B)$9.4B
QIAGEN (QGEN)$9.3B
Roivant Sciences (ROIV)$8.4B
Ascendis Pharma (ASND)$7.5B
Repligen (RGEN)$7.2B
Legend Biotech (LEGN)$7B